Publikationen - Leibniz Universität Hannover

91. Integrierte Versorgung in Deutschland - ein empirisches Schlaglicht. Diskussionspapier Nr.
338, Leibniz Universität Hannover, Mai 2006 (with Schmidt F)
92. Versorgung von HIV-Patienten in Deutschland: Herausforderungen der Zukunft.
Diskussionspapier Nr. 424, Leibniz Universität Hannover, Juli 2009 (with Claes C, Stoll M)
Poster Abstracts in Conference Proceedings
93. What are the determinants (direct, indirect, intangible costs) of economic evaluations in
osteoarthritis? Osteoporosis Int 2003; 14 (Suppl 7): S1-S2
94. Health-related quality of life of patients with rheumatoid arthritis in clinical study settings - A
comparison between EQ-5D, SF-36 and DAS (Disability Assessment Schedule). 20th Plenary
meeting of the EuroQol group, Republic of Slovenia, Ministry of Health, 2003, S. 220
95. Changing costs in rheumatoid arthritis: Methods, trends, and implications. Ann Rheum Dis
2004 July; 63 (Suppl 1): 13-14 (with Ruof J, Merkesdal S, Zeidler H et al)
96. How adequate do RA-patients report indirect costs? The example of a German cohort. Value
Health 2004; 7(6): 664 (with Greiner W, Merkesdal J)
97. Costs of RA in Germany on a micro-costing level. Value Health 2004; 7(6): 664 (with Ruof J)
98. Co-payments in rheumatoid arthritis observed in a German cohort. Value Health 2004; 7(6):
665 (with Hülsemann JL, Ruof, J)
99. Effects of adalimumab mono therapy on health utility and fatigue in patients with long-standing,
severe rheumatoid arthritis (RA). Value Health 2005; 8(3): 342 (with Dietz B, Sterz R,
Cifaldi M et al)
100. Effects of long-term adalimumab therapy on health utility and fatigue in patients with longstanding,
severe rheumatoid arthritis (RA) - Results from a 3-year follow-up study. Value
Health 2005; 8(6): A30
101. Adalimumab treated patients with long-standing rheumatoid arthritis (RA) decrease their
resource utilization during the course of long-term treatment. Rheumatology 2007; 46
(Suppl.1): i103 (with Benter U, Cifaldi M, Dietz BM et al)
102. Cost of illness in rheumatoid arthritis: the pre- and post-era of TNF Blocker introduction in
Germany. Ann Rheum Dis 2007;66 Suppl II:EULAR Abstract THU0462 (with Merkesdal S, Rihi
M)
103. Validity of a child-friendly EQ-5D as a generic health-outcome instrument in children and
adolescents with cystic fibrosis in Germany. Value Health 2007; 10(6): A378 (with Eidt D,
Greiner W, von der Schulenburg, JM)
104. Cost-Effectiveness of Exemestane vs. Tamoxifen in post-menopausal women with early
breast cancer in Germany. Value Health 2007; 10(6): A326. with Braun S, Greiner W, Dopatka J
et al)